Nothing said here yet.
to join the conversation.
| Reardon AndrewCLO & Secretary | Sell | 1,976 | $599.8K | Fri, Oct 2 |
| Reardon AndrewCLO & Secretary | Sell | 1,535 | $467.4K | Fri, Oct 2 |
| Reardon AndrewCLO & Secretary | Sell | 833 | $252.0K | Fri, Oct 2 |
| Reardon AndrewCLO & Secretary | Sell | 404 | $123.7K | Fri, Oct 2 |
| Reardon AndrewCLO & Secretary | Sell | 235 | $72.2K | Fri, Oct 2 |
| Reardon AndrewCLO & Secretary | Sell | 17 | $5.2K | Fri, Oct 2 |
| Zimmermann MartineDirector | Sell | 1,200 | $342.0K | Thu, Sep 10 |
| Reardon AndrewCLO & Secretary | Sell | 2,115 | $605.6K | Thu, Sep 3 |
| Reardon AndrewCLO & Secretary | Sell | 1,800 | $513.3K | Thu, Sep 3 |
| Reardon AndrewCLO & Secretary | Sell | 400 | $115.6K | Thu, Sep 3 |
| Reardon AndrewCLO & Secretary | Sell | 385 | $110.7K | Thu, Sep 3 |
| Reardon AndrewCLO & Secretary | Sell | 300 | $85.2K | Thu, Sep 3 |
| Gilbert Cisneros | Buy | $8.0K | Fri, May 29 | Fri, Jun 5 |
Ligand Pharmaceuticals (LGND) raised its 2026 adjusted EPS guidance but maintained its royalty and t
Ligand Pharmaceuticals just posted Q3 2026 results, and the story the numbers tell is very different from the mood on the screen.
Royalty revenue surged 51% on XOMA acquisition and Filspari momentum.
Ligand Pharmaceuticals (NASDAQ:LGND) reported third-quarter royalty revenue growth of 51% year over year to approximately $70 million, driven by Filspari, Ohtuvayre and commercial assets acquired through its July purchase of XOMA Royalty.
(AP) — Ligand Pharmaceuticals Inc. (LGND) on Thursday reported a loss of $28.
Why the AvenCell financing matters for Ligand Pharmaceuticals Ligand Pharmaceuticals (LGND) has agreed to provide up to $47 million in funding to AvenCell Therapeutics, tying most of the capital to clinical milestones in AvenCell’s CAR-T therapy programs.